SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors
Standard
SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors. / Dum, David; Kromm, Daniela; Lennartz, Maximilian; De Wispelaere, Noémi; Büscheck, Franziska; Luebke, Andreas M; Burandt, Eike; Menz, Anne; Kluth, Martina; Hube-Magg, Claudia; Hinsch, Andrea; Höflmayer, Doris; Weidemann, Sören; Fraune, Christoph; Möller, Katharina; Lebok, Patrick; Sauter, Guido; Simon, Ronald; Uhlig, Ria; Wilczak, Waldemar; Minner, Sarah; Krech, Rainer; Bernreuther, Christian; Marx, Andreas; Steurer, Stefan; Jacobsen, Frank; Clauditz, Till; Krech, Till.
In: ARCH PATHOL LAB MED, Vol. 147, No. 4, 01.04.2023, p. 451-464.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors
AU - Dum, David
AU - Kromm, Daniela
AU - Lennartz, Maximilian
AU - De Wispelaere, Noémi
AU - Büscheck, Franziska
AU - Luebke, Andreas M
AU - Burandt, Eike
AU - Menz, Anne
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Hinsch, Andrea
AU - Höflmayer, Doris
AU - Weidemann, Sören
AU - Fraune, Christoph
AU - Möller, Katharina
AU - Lebok, Patrick
AU - Sauter, Guido
AU - Simon, Ronald
AU - Uhlig, Ria
AU - Wilczak, Waldemar
AU - Minner, Sarah
AU - Krech, Rainer
AU - Bernreuther, Christian
AU - Marx, Andreas
AU - Steurer, Stefan
AU - Jacobsen, Frank
AU - Clauditz, Till
AU - Krech, Till
N1 - © 2022 College of American Pathologists.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - CONTEXT.—: Special AT-rich sequence-binding protein 2 (SATB2) induces local chromatin loops to facilitate transcription. SATB2 immunostaining is commonly used as a marker for colorectal adenocarcinoma and osteosarcoma.OBJECTIVE.—: To extend our knowledge on the diagnostic value of SATB2 analysis in a comprehensive set of human tumors.DESIGN.—: Tissue microarrays with 15 012 samples from 120 tumor types and 608 samples of 76 different normal tissues were analyzed.RESULTS.—: SATB2 positivity was found in 89 of 120 different tumor types (74%), including 59 of 120 (49%) with at least 1 moderately positive tumor and 38 of 120 tumor types (32%) with at least 1 strongly positive tumor. Expression was frequent in adenomas (44/42-47/44; 94%-96% positive), adenocarcinomas (1747 of 2023; 86%) and various subtypes of neuroendocrine neoplasms (3/7-12/12; 43%-100%) of the colorectum and appendix, Merkel cell carcinoma (25 of 34, 74%), osteosarcomas (15 of 25; 60%), and papillary renal cell carcinoma (RCC) (121 of 235; 52%). Associations to clinicopathologic tumor features were assessed in colorectal and kidney cancers. In colorectal cancer, weak SATB2 expression was linked to high pT (P < .001), nodal metastasis (P < .001), right-sided tumor location (P < .001), microsatellite instability (P < .001), and BRAF mutations (P = .02). In papillary RCC, low SATB2 expression was associated with high pT (P = .02), distant metastasis (P = .04), and reduced tumor-specific survival (P = .04). In clear cell RCC, low SATB2 expression was linked to high pT (P < .001), high Union for International Cancer Control stage (P < .001), high Thoenes grade (P = .02), and reduced recurrence-free survival (P = .02).CONCLUSIONS.—: Strong SATB2 expression argues for a colorectal origin within adenocarcinomas and neuroendocrine neoplasms. Weak SATB2 expression reflects progression and poor prognosis in colorectal and kidney cancer.
AB - CONTEXT.—: Special AT-rich sequence-binding protein 2 (SATB2) induces local chromatin loops to facilitate transcription. SATB2 immunostaining is commonly used as a marker for colorectal adenocarcinoma and osteosarcoma.OBJECTIVE.—: To extend our knowledge on the diagnostic value of SATB2 analysis in a comprehensive set of human tumors.DESIGN.—: Tissue microarrays with 15 012 samples from 120 tumor types and 608 samples of 76 different normal tissues were analyzed.RESULTS.—: SATB2 positivity was found in 89 of 120 different tumor types (74%), including 59 of 120 (49%) with at least 1 moderately positive tumor and 38 of 120 tumor types (32%) with at least 1 strongly positive tumor. Expression was frequent in adenomas (44/42-47/44; 94%-96% positive), adenocarcinomas (1747 of 2023; 86%) and various subtypes of neuroendocrine neoplasms (3/7-12/12; 43%-100%) of the colorectum and appendix, Merkel cell carcinoma (25 of 34, 74%), osteosarcomas (15 of 25; 60%), and papillary renal cell carcinoma (RCC) (121 of 235; 52%). Associations to clinicopathologic tumor features were assessed in colorectal and kidney cancers. In colorectal cancer, weak SATB2 expression was linked to high pT (P < .001), nodal metastasis (P < .001), right-sided tumor location (P < .001), microsatellite instability (P < .001), and BRAF mutations (P = .02). In papillary RCC, low SATB2 expression was associated with high pT (P = .02), distant metastasis (P = .04), and reduced tumor-specific survival (P = .04). In clear cell RCC, low SATB2 expression was linked to high pT (P < .001), high Union for International Cancer Control stage (P < .001), high Thoenes grade (P = .02), and reduced recurrence-free survival (P = .02).CONCLUSIONS.—: Strong SATB2 expression argues for a colorectal origin within adenocarcinomas and neuroendocrine neoplasms. Weak SATB2 expression reflects progression and poor prognosis in colorectal and kidney cancer.
KW - Adenocarcinoma/genetics
KW - Biomarkers, Tumor/analysis
KW - Bone Neoplasms/genetics
KW - Carcinoma, Renal Cell
KW - Colorectal Neoplasms/diagnosis
KW - Humans
KW - Immunohistochemistry
KW - Kidney Neoplasms
KW - Matrix Attachment Region Binding Proteins/analysis
KW - Neuroendocrine Tumors
KW - Osteosarcoma
KW - Transcription Factors/analysis
U2 - 10.5858/arpa.2021-0317-OA
DO - 10.5858/arpa.2021-0317-OA
M3 - SCORING: Journal article
C2 - 35917493
VL - 147
SP - 451
EP - 464
JO - ARCH PATHOL LAB MED
JF - ARCH PATHOL LAB MED
SN - 0003-9985
IS - 4
ER -
